Outcomes of patients with stage III non-small cell lung cancer (NSCLC) that harbor a <i>STK11</i> mutation.

Transl Lung Cancer Res · 2021 · PMC8435393 · PMID 34584860

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Univariate analysis showed a trend towards worse PFS for STK11 m compared to STK11 w patients; however, this was not statistically significant (HR 1.92, 95% CI, 0.91–4.06, P=0.09) ( Figure 1 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.